ToxicityHemolyticPositive observation
Record detail Table 1: Mastoparan (L) HRBC EC50 82.9 ± 3.8 μM
- Measure
- EC50
- Value
- 82.9 ± 3.8 µM
- Target
- Homo sapiens
- Assay
- Not reported by source
Primary literature evidence
Experimental evidence search
Search paper-level observations with their value, target, assay, evidence sentence, source location, and stable record links. Evidence without a safely standardized sequence remains visible without being misrepresented as a canonical peptide.
Evidence records
4 results
ToxicityHemolyticPositive observation
Record detail Table 1: Mastoparan (L) RRBC EC50 242.5 ± 2.6 μM
- Measure
- EC50
- Value
- 242.5 ± 2.6 µM
- Target
- Rattus norvegicus
- Assay
- Not reported by source
AnticancerCytotoxicPositive observation
Record detail These stapled peptides were evaluated for cytotoxicity in the CRC cell line CT26 in vitro, IC50 values ranged from 1.11 μM to 9.32 μM. These stapled MP derivatives exhibited either enhanced or same anti-CRC activity, in comparison to the parent MP.
- Measure
- other
- Value
- IC50 values ranged from 1.11 μM to 9.32 μM for stapled peptides; MP IC50 not explicitly given but stated stapled derivatives exhibited enhanced or same anti-CRC activity compared to parent MP
- Target
- CT26
- Assay
- Not reported by source
ToxicityHemolyticPositive observation
Record detail The potential of the stapled MP peptides to non-specifically lyse red blood cells (RBC) was measured and their hemolytic activities (HC50) determined. The peptide MP9 displayed the lowest level of RBC hemolysis.
- Measure
- HD50
- Value
- HC50 values not explicitly given for MP; MP9 displayed the lowest level of RBC hemolysis
- Target
- Mus musculus
- Assay
- Not reported by source
Names such as P1, PEP1, or peptide 1 are paper-local labels. Search results group them by publication and never assume cross-paper molecular identity without sequence or explicit structural evidence.